New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies.

A new series of PPARgamma ligands based on barbituric acid (BA) has been designed employing virtual screening and molecular docking approach. To validate the computational approach, designed molecules were synthesized and evaluated in in vitro radioligand binding studies. Out of the total 14 molecules, 6 were found to bind to the murine PPARgamma with IC(50) ranging from 0.1 to 2.5 microM as compared to reference standard, pioglitazone (IC(50)=0.7 microM).

[1]  T. Sohda,et al.  Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents. , 2002, Chemical & pharmaceutical bulletin.

[2]  G. Klebe.  Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.

[3]  Prasad V Bharatam,et al.  New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies. , 2008, Bioorganic & medicinal chemistry letters.

[4]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[5]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[6]  V. Motilva,et al.  New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists , 2004 .

[7]  A. Burdick,et al.  The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  D. Bishop-Bailey,et al.  Peroxisome proliferator-activated receptors and inflammation. , 2006, Pharmacology & therapeutics.

[9]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[10]  R. Castle.  Topics in heterocyclic chemistry , 1969 .

[11]  H. Koeffler.  Peroxisome proliferator-activated receptor γ and cancers , 2003 .

[12]  Liang Guo,et al.  Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. , 2006, Pharmacology & therapeutics.

[13]  Rakesh Kumar,et al.  Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARγ activators , 2007 .

[14]  B. Staels,et al.  Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis , 2006, Expert opinion on emerging drugs.

[15]  Ingo Muegge,et al.  Advances in virtual screening , 2006, Drug Discovery Today: Technologies.

[16]  B. Staels,et al.  The role of PPARs in atherosclerosis. , 2002, Trends in molecular medicine.

[17]  Rakesh Kumar,et al.  Studies on some glitazones having pyridine as the linker unit. , 2004, Bioorganic & medicinal chemistry.

[18]  Rakesh Kumar,et al.  Synthesis, in vitro and in silico evaluation of l-tyrosine containing PPARα/γ dual agonists , 2007 .

[19]  T. Sohda,et al.  Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. , 1982, Chemical & pharmaceutical bulletin.

[20]  P. Bharatam,et al.  Additivity of Molecular Fields: CoMFA Study on Dual Activators of PPARα and PPARγ , 2005 .

[21]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[22]  J Auwerx,et al.  Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.

[23]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Moulder,et al.  Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells (*) , 1995, The Journal of Biological Chemistry.

[25]  L. Gediya,et al.  Three-dimensional quantitative structure activity relationships (3-D-QSAR) of antihyperglycemic agents. , 1999, Bioorganic & medicinal chemistry.

[26]  J. Lehmann,et al.  N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.

[27]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[28]  D. Hum,et al.  Safety issues and prospects for future generations of PPAR modulators. , 2007, Biochimica et biophysica acta.

[29]  P. Ramarao,et al.  AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. , 2005, Cardiovascular research.

[30]  S. Kersten.  Peroxisome proliferator activated receptors and obesity. , 2002, European journal of pharmacology.

[31]  M. Kawada,et al.  Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities. , 2002, Journal of medicinal chemistry.

[32]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[33]  B. Jursic.  A simple method for knoevenagel condensation of α,β‐conjugated and aromatic aldehydes with barbituric acid , 2001 .

[34]  I. Lu,et al.  Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.